Salarius Pharmaceuticals, Inc. - SLRX STOCK NEWS

Salarius Pharmaceuticals (Nasdaq: SLRX) has received a $2.7 million payment under its existing contract with the Cancer Prevention and Research Institute of Texas (CPRIT) to support its lead drug candidate, seclidemstat. This funding adds to the $33 million already reported on its balance sheet as of June 30, 2021, with up to $2.1 million remaining under the original CPRIT award. Seclidemstat is being studied for various cancers, including Ewing sarcoma, with clinical trials underway across five patient groups.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 10:50 a.m. ET. The event will be accessible virtually to registered attendees. Arthur will discuss Salarius’ recent achievements and highlight the clinical trial for seclidemstat, an oral LSD1 inhibitor, which is targeting Ewing sarcoma and other cancers. The company also plans virtual one-on-one meetings with investors. A recording of the presentation will be available on Salarius’ website post-event.

Salarius Pharmaceuticals (Nasdaq: SLRX) has announced a partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to explore new indications and potential biomarkers for its lead drug candidate, seclidemstat. This oral inhibitor targets lysine-specific histone demethylase 1 (LSD1), a key enzyme in cancer progression. A Phase 1/2 trial is ongoing for sarcomas and now includes hematologic cancers. CEO David Arthur emphasized the collaboration as a validation of seclidemstat's potential and aims to provide new treatment options for patients with difficult-to-treat cancers.

Salarius Pharmaceuticals (Nasdaq: SLRX) has been included in the FTSE Global Micro Cap Index, effective September 20, 2021. This milestone is aimed at enhancing the company's visibility among institutional investors and increasing stock liquidity, as noted by CEO David Arthur. The FTSE Global Micro Cap Index comprises 8,832 companies with a net market capitalization of $1.89 trillion, with 47% of its constituents based in the U.S. and 17.65% from the healthcare sector. This inclusion signals a positive year for Salarius, aligned with its ongoing clinical programs.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Life Science Investor Forum on September 16, 2021. The presentation, accessible to registered attendees, will cover the company's recent advancements and the clinical progress of seclidemstat, an oral LSD1 inhibitor. This drug is under evaluation in a Phase 1/2 trial for Ewing sarcoma and other cancers. Participants can also follow up with a recorded version of the presentation on the company's website after the event.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation, accessible to registered attendees starting at 7 a.m. ET on September 13, will cover the company's business overview, recent achievements, and clinical milestones for seclidemstat, an LSD1 inhibitor in trials for Ewing sarcoma and hematologic cancers. Salarius will also engage in one-on-one meetings with investors and pharmaceutical executives.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) has announced that CEO David Arthur will present at the Diamond Equity Research Emerging Growth Invitational Conference on August 17, 2021, at 11 a.m. ET. The presentation will cover the company's business highlights, recent achievements, and future clinical milestones for seclidemstat, an oral LSD1 inhibitor. Salarius is advancing a Phase 1/2 clinical trial for Ewing sarcoma and other cancers. Interested participants can register for the event at no cost, with a recording available post-event on Salarius' website.

Salarius Pharmaceuticals (Nasdaq: SLRX) recently reported significant developments during Q2 2021, including the commencement of clinical trials for its lead drug candidate, seclidemstat, in various cancer types. The company has cash reserves of $33.1 million, enough to fund ongoing clinical programs. Initial findings presented at ASCO 2021 indicated preliminary efficacy for seclidemstat, with a manageable safety profile. A Phase 1/2 trial is underway for treating hematologic cancers in collaboration with MD Anderson Cancer Center, while multiple new sites and patient groups are being added for sarcoma studies.

Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call and live audio webcast on August 5, 2021, at 10:00 a.m. ET to discuss its second quarter and year-to-date 2021 financial results. The conference call can be accessed via phone or through the company’s website. Salarius is focused on developing cancer therapies, particularly its lead candidate, seclidemstat, which is in a Phase 1/2 clinical trial for various sarcomas, including Ewing sarcoma. The company has received several designations from the U.S. FDA to support its work.